The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biosimilar of Remicade-Global Market Insights and Sales Trends 2024
Synopsis
A biosimilar of Remicade is a biologic medication that is highly similar to the reference product, Remicade, in terms of safety, efficacy, and quality.
The global Biosimilar of Remicade market size is expected to reach US$ 491720 million by 2029, growing at a CAGR of 7.2% from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilar of Remicade in various end use industries. The expanding demands from the Tumor, Diabetes, Cardiovascular and Hemophilia, are propelling Biosimilar of Remicade market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interferon segment is estimated at % CAGR for the next seven-year period.
The market for biosimilars of Remicade is driven by the increasing adoption of biosimilar therapies and the need for affordable treatment options for autoimmune diseases. The market's growth is also influenced by the presence of well-established regulatory pathways for biosimilar approval and the entry of multiple biosimilar manufacturers into the market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilar of Remicade, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilar of Remicade market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilar of Remicade market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilar of Remicade sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilar of Remicade covered in this report include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc.
The global Biosimilar of Remicade market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Global Biosimilar of Remicade market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilar of Remicade market, Segment by Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Global Biosimilar of Remicade market, by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilar of Remicade companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A biosimilar of Remicade is a biologic medication that is highly similar to the reference product, Remicade, in terms of safety, efficacy, and quality.
The global Biosimilar of Remicade market size is expected to reach US$ 491720 million by 2029, growing at a CAGR of 7.2% from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilar of Remicade in various end use industries. The expanding demands from the Tumor, Diabetes, Cardiovascular and Hemophilia, are propelling Biosimilar of Remicade market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interferon segment is estimated at % CAGR for the next seven-year period.
The market for biosimilars of Remicade is driven by the increasing adoption of biosimilar therapies and the need for affordable treatment options for autoimmune diseases. The market's growth is also influenced by the presence of well-established regulatory pathways for biosimilar approval and the entry of multiple biosimilar manufacturers into the market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilar of Remicade, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilar of Remicade market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilar of Remicade market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilar of Remicade sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilar of Remicade covered in this report include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc.
The global Biosimilar of Remicade market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Global Biosimilar of Remicade market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilar of Remicade market, Segment by Type:
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Global Biosimilar of Remicade market, by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilar of Remicade companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Biosimilar of Remicade
1.1 Biosimilar of Remicade Market Overview
1.1.1 Biosimilar of Remicade Product Scope
1.1.2 Biosimilar of Remicade Market Status and Outlook
1.2 Global Biosimilar of Remicade Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biosimilar of Remicade Market Size by Region (2018-2029)
1.4 Global Biosimilar of Remicade Historic Market Size by Region (2018-2023)
1.5 Global Biosimilar of Remicade Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biosimilar of Remicade Market Size (2018-2029)
1.6.1 North America Biosimilar of Remicade Market Size (2018-2029)
1.6.2 Europe Biosimilar of Remicade Market Size (2018-2029)
1.6.3 Asia-Pacific Biosimilar of Remicade Market Size (2018-2029)
1.6.4 Latin America Biosimilar of Remicade Market Size (2018-2029)
1.6.5 Middle East & Africa Biosimilar of Remicade Market Size (2018-2029)
2 Biosimilar of Remicade Market by Type
2.1 Introduction
2.1.1 Monoclonal Antibodies
2.1.2 Interferon
2.1.3 Erythropoietin
2.1.4 Insulin
2.1.5 Vaccines
2.1.6 Other
2.2 Global Biosimilar of Remicade Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biosimilar of Remicade Historic Market Size by Type (2018-2023)
2.2.2 Global Biosimilar of Remicade Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biosimilar of Remicade Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biosimilar of Remicade Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biosimilar of Remicade Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biosimilar of Remicade Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biosimilar of Remicade Revenue Breakdown by Type (2018-2029)
3 Biosimilar of Remicade Market Overview by Application
3.1 Introduction
3.1.1 Tumor
3.1.2 Diabetes
3.1.3 Cardiovascular
3.1.4 Hemophilia
3.1.5 Other
3.2 Global Biosimilar of Remicade Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biosimilar of Remicade Historic Market Size by Application (2018-2023)
3.2.2 Global Biosimilar of Remicade Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biosimilar of Remicade Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biosimilar of Remicade Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biosimilar of Remicade Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biosimilar of Remicade Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biosimilar of Remicade Revenue Breakdown by Application (2018-2029)
4 Biosimilar of Remicade Competition Analysis by Players
4.1 Global Biosimilar of Remicade Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilar of Remicade as of 2022)
4.3 Date of Key Players Enter into Biosimilar of Remicade Market
4.4 Global Top Players Biosimilar of Remicade Headquarters and Area Served
4.5 Key Players Biosimilar of Remicade Product Solution and Service
4.6 Competitive Status
4.6.1 Biosimilar of Remicade Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Biosimilar of Remicade Products, Services and Solutions
5.1.4 Roche Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Biosimilar of Remicade Products, Services and Solutions
5.2.4 Amgen Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Biosimilar of Remicade Products, Services and Solutions
5.3.4 AbbVie Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi-Aventis Recent Developments
5.4 Sanofi-Aventis
5.4.1 Sanofi-Aventis Profile
5.4.2 Sanofi-Aventis Main Business
5.4.3 Sanofi-Aventis Biosimilar of Remicade Products, Services and Solutions
5.4.4 Sanofi-Aventis Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi-Aventis Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Biosimilar of Remicade Products, Services and Solutions
5.5.4 Johnson & Johnson Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Biosimilar of Remicade Products, Services and Solutions
5.6.4 Pfizer Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Novo Nordisk
5.7.1 Novo Nordisk Profile
5.7.2 Novo Nordisk Main Business
5.7.3 Novo Nordisk Biosimilar of Remicade Products, Services and Solutions
5.7.4 Novo Nordisk Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.7.5 Novo Nordisk Recent Developments
5.8 Eli Lilly
5.8.1 Eli Lilly Profile
5.8.2 Eli Lilly Main Business
5.8.3 Eli Lilly Biosimilar of Remicade Products, Services and Solutions
5.8.4 Eli Lilly Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.8.5 Eli Lilly Recent Developments
5.9 Novartis
5.9.1 Novartis Profile
5.9.2 Novartis Main Business
5.9.3 Novartis Biosimilar of Remicade Products, Services and Solutions
5.9.4 Novartis Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.9.5 Novartis Recent Developments
5.10 Merck
5.10.1 Merck Profile
5.10.2 Merck Main Business
5.10.3 Merck Biosimilar of Remicade Products, Services and Solutions
5.10.4 Merck Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Recent Developments
5.11 3sbio
5.11.1 3sbio Profile
5.11.2 3sbio Main Business
5.11.3 3sbio Biosimilar of Remicade Products, Services and Solutions
5.11.4 3sbio Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.11.5 3sbio Recent Developments
5.12 Changchun High Tech
5.12.1 Changchun High Tech Profile
5.12.2 Changchun High Tech Main Business
5.12.3 Changchun High Tech Biosimilar of Remicade Products, Services and Solutions
5.12.4 Changchun High Tech Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.12.5 Changchun High Tech Recent Developments
5.13 CP Guojian
5.13.1 CP Guojian Profile
5.13.2 CP Guojian Main Business
5.13.3 CP Guojian Biosimilar of Remicade Products, Services and Solutions
5.13.4 CP Guojian Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.13.5 CP Guojian Recent Developments
5.14 Biotech
5.14.1 Biotech Profile
5.14.2 Biotech Main Business
5.14.3 Biotech Biosimilar of Remicade Products, Services and Solutions
5.14.4 Biotech Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.14.5 Biotech Recent Developments
5.15 Gelgen
5.15.1 Gelgen Profile
5.15.2 Gelgen Main Business
5.15.3 Gelgen Biosimilar of Remicade Products, Services and Solutions
5.15.4 Gelgen Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.15.5 Gelgen Recent Developments
5.16 Innovent
5.16.1 Innovent Profile
5.16.2 Innovent Main Business
5.16.3 Innovent Biosimilar of Remicade Products, Services and Solutions
5.16.4 Innovent Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.16.5 Innovent Recent Developments
5.17 Dong Bao
5.17.1 Dong Bao Profile
5.17.2 Dong Bao Main Business
5.17.3 Dong Bao Biosimilar of Remicade Products, Services and Solutions
5.17.4 Dong Bao Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.17.5 Dong Bao Recent Developments
5.18 Ganlee
5.18.1 Ganlee Profile
5.18.2 Ganlee Main Business
5.18.3 Ganlee Biosimilar of Remicade Products, Services and Solutions
5.18.4 Ganlee Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.18.5 Ganlee Recent Developments
5.19 United Laboratories
5.19.1 United Laboratories Profile
5.19.2 United Laboratories Main Business
5.19.3 United Laboratories Biosimilar of Remicade Products, Services and Solutions
5.19.4 United Laboratories Biosimilar of Remicade Revenue (US$ Million) & (2018-2023)
5.19.5 United Laboratories Recent Developments
6 North America
6.1 North America Biosimilar of Remicade Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Biosimilar of Remicade Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar of Remicade Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biosimilar of Remicade Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar of Remicade Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biosimilar of Remicade Market Dynamics
11.1 Biosimilar of Remicade Industry Trends
11.2 Biosimilar of Remicade Market Drivers
11.3 Biosimilar of Remicade Market Challenges
11.4 Biosimilar of Remicade Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
